US7011834B1
(en)
*
|
1987-01-30 |
2006-03-14 |
The Board Of Trustees Of Leland Stanford Junior University |
Immunomodulating dimers
|
US6479632B1
(en)
*
|
1988-09-12 |
2002-11-12 |
Yeda Research And Development Co. Ltd. |
Tumor necrosis factor inhibitory protein and its purification
|
IL83878A
(en)
*
|
1987-09-13 |
1995-07-31 |
Yeda Res & Dev |
Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
|
IL98078A0
(en)
*
|
1991-05-07 |
1992-06-21 |
Yeda Res & Dev |
Pharmaceutical compositions comprising an anticytokyne
|
US5512544A
(en)
*
|
1987-09-13 |
1996-04-30 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising an anticytokine
|
ES2238070T3
(es)
|
1989-04-21 |
2005-08-16 |
Amgen Inc. |
Receptor del tnf, proteina ligante del tnf y adn codante para estos.
|
US6221675B1
(en)
|
1989-04-21 |
2001-04-24 |
Amgen, Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
US7264944B1
(en)
*
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
ATE194384T1
(de)
|
1989-09-12 |
2000-07-15 |
Hoffmann La Roche |
Tnf-bindende proteine
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US5919452A
(en)
*
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
US5656272A
(en)
*
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
US5698195A
(en)
*
|
1991-03-18 |
1997-12-16 |
New York University Medical Center |
Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
ATE242322T1
(de)
*
|
1992-03-30 |
2003-06-15 |
Immunex Corp |
Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
|
US20050260201A1
(en)
*
|
1993-01-29 |
2005-11-24 |
Centocor, Inc. |
Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
|
CA2119089A1
(en)
*
|
1993-03-29 |
1994-09-30 |
David Banner |
Tumor necrosis factor muteins
|
EP0732938A4
(de)
*
|
1993-12-01 |
1997-03-19 |
Unisearch Ltd |
Verfahren zur behandlung von intestinalen störungen
|
NZ278607A
(en)
*
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
US5712381A
(en)
*
|
1994-10-19 |
1998-01-27 |
Genetics Institute, Inc. |
MADD, a TNF receptor death domain ligand protein
|
US5852173A
(en)
*
|
1994-10-19 |
1998-12-22 |
Genetics Institute, Inc. |
TNF receptor death ligand proteins and inhibitors of ligand binding
|
US5847099A
(en)
*
|
1994-10-19 |
1998-12-08 |
Genetics Institute, Inc. |
TNF receptor death domain ligand proteins
|
US5849501A
(en)
*
|
1994-10-19 |
1998-12-15 |
Genetics Institute, Inc. |
TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
IL117175A
(en)
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
IL112834A
(en)
*
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US7070783B1
(en)
*
|
1995-05-09 |
2006-07-04 |
The Mathilda And Terence Kennedy Institute Of Rheumatology |
Small molecular weight TNF receptor multimeric molecule
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
NZ331539A
(en)
*
|
1996-02-20 |
2000-01-28 |
Applied Research Systems |
Hybrid proteins from two coexpressed receptors to form a heterodimer
|
EP1541689B1
(de)
|
1996-02-20 |
2012-09-05 |
Merck Serono SA |
Heterodimerebildende Hybrid-Proteine
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US7357927B2
(en)
*
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
AU2213697A
(en)
*
|
1996-03-18 |
1997-10-10 |
Medical Science Systems, Inc. |
A method for periodontal disease treatment
|
TW555765B
(en)
*
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
AU5696198A
(en)
|
1996-12-06 |
1998-06-29 |
Amgen, Inc. |
Combination therapy using a tnf binding protein for treating tnf-mediated diseases
|
EP2002846B1
(de)
|
1996-12-06 |
2017-01-25 |
Amgen Inc. |
Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten
|
JP4138013B2
(ja)
|
1996-12-23 |
2008-08-20 |
イミュネックス・コーポレーション |
Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド
|
US6455040B1
(en)
*
|
1997-01-14 |
2002-09-24 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptor 5
|
US6433147B1
(en)
|
1997-01-28 |
2002-08-13 |
Human Genome Sciences, Inc. |
Death domain containing receptor-4
|
US6342363B1
(en)
*
|
1997-01-28 |
2002-01-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 nucleic acids and methods
|
US8329179B2
(en)
*
|
1997-01-28 |
2012-12-11 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
US7452538B2
(en)
|
1997-01-28 |
2008-11-18 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
EP0970213B1
(de)
*
|
1997-03-17 |
2007-01-24 |
Human Genome Sciences, Inc. |
Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
JP3523650B2
(ja)
|
1997-04-15 |
2004-04-26 |
三共株式会社 |
新規蛋白質及びその製造方法
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
IL132304A0
(en)
|
1997-04-16 |
2001-03-19 |
Amgen Inc |
Osteoprotegerin binding proteins and receptors
|
EP0980432A1
(de)
*
|
1997-05-01 |
2000-02-23 |
Amgen, Inc. |
Chimäre opg-polypeptide.
|
US6187564B1
(en)
*
|
1997-07-10 |
2001-02-13 |
Beth Israel Deaconess Medical Center |
DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
|
US6287558B1
(en)
|
1997-08-01 |
2001-09-11 |
Biohybrio Technologies Llc |
Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
|
US7704944B2
(en)
*
|
1997-08-14 |
2010-04-27 |
Yeda Research And Development Company Ltd. |
Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6893838B1
(en)
|
1998-04-07 |
2005-05-17 |
Genetics Institute Llc |
DADD, death activator death domain protein
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
CN1317291C
(zh)
*
|
1999-09-10 |
2007-05-23 |
杰龙公司 |
寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
|
AR025984A1
(es)
*
|
1999-10-07 |
2002-12-26 |
Maxygen Aps |
Polipeptidos oligomericos de cadena simple
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
US7446174B2
(en)
|
2001-03-02 |
2008-11-04 |
Xencor, Inc. |
Protein based TNF-α variants for the treatment of TNF-α related disorders
|
US7244823B2
(en)
*
|
2000-03-02 |
2007-07-17 |
Xencor |
TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
|
US7056695B2
(en)
|
2000-03-02 |
2006-06-06 |
Xencor |
TNF-α variants
|
US7662367B2
(en)
*
|
2000-03-02 |
2010-02-16 |
Xencor, Inc. |
Pharmaceutical compositions for the treatment of TNF-α related disorders
|
EP1259616A2
(de)
|
2000-03-02 |
2002-11-27 |
Xencor |
Tnf-alpha varianten für die behandlung von erkrankungen, die mit tnf-alpha zusammenhängen
|
US20070172449A1
(en)
*
|
2000-03-02 |
2007-07-26 |
Xencor, Inc. |
TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
|
US7687461B2
(en)
*
|
2000-03-02 |
2010-03-30 |
Xencor, Inc. |
Treatment of TNF-α related disorders with TNF-α variant proteins
|
US7101974B2
(en)
|
2000-03-02 |
2006-09-05 |
Xencor |
TNF-αvariants
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
KR20120053525A
(ko)
|
2000-06-16 |
2012-05-25 |
캠브리지 안티바디 테크놀로지 리미티드 |
면역특이적으로 BLyS에 결합하는 항체
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
EP1683865A3
(de)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Säugerproteine und insbesondere CD200
|
CN1564826A
(zh)
|
2001-02-09 |
2005-01-12 |
人类基因组科学公司 |
人类g蛋白趋化因子受体(ccr5)hdgnr10
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
US20050129616A1
(en)
*
|
2001-05-25 |
2005-06-16 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
WO2002097033A2
(en)
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
TR201809008T4
(tr)
|
2001-06-26 |
2018-07-23 |
Amgen Fremont Inc |
Opgl ye karşi antikorlar.
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
AU2002361784A1
(en)
*
|
2001-12-20 |
2003-07-09 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
AU2003218456A1
(en)
*
|
2002-04-01 |
2003-10-20 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
PL375041A1
(en)
|
2002-04-05 |
2005-11-14 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
JP2006517191A
(ja)
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
EP1585815A4
(de)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
|
EP1590458B1
(de)
|
2003-02-06 |
2012-10-31 |
Queen's University Of Belfast |
Ein auf den bradykinin b2-rezeptor antagonistisch wirkendes peptid aus amphibienhaut
|
US7892563B2
(en)
|
2003-05-20 |
2011-02-22 |
Wyeth Holdings Corporation |
Methods for treatment of severe acute respiratory syndrome (SARS)
|
US20050281799A1
(en)
|
2004-06-16 |
2005-12-22 |
Glen Gong |
Targeting damaged lung tissue using compositions
|
US20050281740A1
(en)
*
|
2004-06-16 |
2005-12-22 |
Glen Gong |
Imaging damaged lung tissue
|
US7608579B2
(en)
|
2004-06-16 |
2009-10-27 |
Pneumrx, Inc. |
Lung volume reduction using glue compositions
|
US7678767B2
(en)
|
2004-06-16 |
2010-03-16 |
Pneumrx, Inc. |
Glue compositions for lung volume reduction
|
US7553810B2
(en)
|
2004-06-16 |
2009-06-30 |
Pneumrx, Inc. |
Lung volume reduction using glue composition
|
WO2006014567A2
(en)
|
2004-07-08 |
2006-02-09 |
Pneumrx, Inc. |
Pleural effusion treatment device, method and material
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
CA2663548A1
(en)
*
|
2006-09-12 |
2008-03-20 |
Cosmo Technologies Ltd |
Pharmaceutical compositions for the oral or rectal administration of protein substances
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
EP2099916A2
(de)
*
|
2006-12-22 |
2009-09-16 |
Dow AgroSciences LLC |
Aus pflanzen hergestellte west-nil-virus-impfstoffe, vektoren und pflanzencodonoptimierte sequenzen
|
US20080293053A1
(en)
*
|
2006-12-28 |
2008-11-27 |
The Regents Of The University Of Michigan |
shRNA Materials and Methods of Using Same for Inhibition of DKK-1
|
SI2279007T1
(sl)
|
2008-04-29 |
2016-09-30 |
Ascendis Pharma Growth Disorders Division A/S |
Spojine pegiliranega rekombinantnega humanega rastnega hormona
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
SG181648A1
(en)
|
2009-12-15 |
2012-07-30 |
Ascendis Pharma As |
Dry growth hormone composition transiently linked to a polymer carrier
|
EP3295957B1
(de)
|
2010-01-15 |
2019-08-07 |
Kirin-Amgen, Inc. |
Anti il-17ra-antikörperformulierung und therapeutische regimen zur behandlung von psoriasis
|
CA2793838C
(en)
|
2010-03-19 |
2019-09-17 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Integrin interaction inhibitors for the treatment of cancer
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN103119054B
(zh)
|
2010-03-26 |
2017-01-18 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
CN102219859B
(zh)
|
2011-05-20 |
2012-09-12 |
烟台荣昌生物工程有限公司 |
拮抗血管新生诱导因子的融合蛋白及其用途
|
CN102219860B
(zh)
|
2011-05-20 |
2012-09-12 |
烟台荣昌生物工程有限公司 |
FGFR-Fc融合蛋白及其用途
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AU2013312211B2
(en)
|
2012-09-07 |
2018-03-29 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3087098B1
(de)
|
2013-12-24 |
2020-04-08 |
Janssen Pharmaceutica NV |
Anti-vista-antikörper und -fragmente
|
KR20160130248A
(ko)
|
2014-03-31 |
2016-11-10 |
키린-암젠, 인코포레이티드 |
손발톱 및 두피 건선의 치료 방법
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
EP3191131A4
(de)
|
2014-08-21 |
2018-09-05 |
The General Hospital Corporation |
Tumornekrosefaktor-superfamilie und tnf-like-ligand-muteine sowie verfahren zur herstellung und verwendung davon
|
EP3226900A4
(de)
*
|
2014-12-05 |
2018-09-19 |
Immunext, Inc. |
Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
|
WO2016207717A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
IL294679B2
(en)
|
2015-08-07 |
2023-10-01 |
Alx Oncology Inc |
Structures with a SIRP-alpha site or its variant
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
EP3442579A4
(de)
|
2016-04-15 |
2019-12-18 |
Immunext Inc. |
Anti-human-vista-antikörper und verwendung davon
|
WO2018140121A1
(en)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
KR20240038148A
(ko)
|
2017-02-07 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
WO2020114411A1
(zh)
|
2018-12-07 |
2020-06-11 |
荣昌生物制药(烟台)有限公司 |
一种双功能血管生成抑制剂及其用途
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
CA3141130A1
(en)
|
2019-05-31 |
2020-12-03 |
ALX Oncology Inc. |
Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
|